News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
107 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53928)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (19233)
Month
January (2433)
February (2866)
March (3029)
April (3115)
May (3356)
June (2725)
July (1709)
Day
1 (121)
2 (97)
3 (8)
5 (6)
6 (79)
7 (151)
8 (89)
9 (80)
10 (30)
13 (139)
14 (106)
15 (102)
16 (135)
17 (48)
19 (25)
20 (84)
21 (88)
22 (116)
23 (109)
24 (78)
26 (6)
27 (12)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
Day
1
2
3
5
6
7
8
9
10
13
14
15
16
17
19
20
21
22
23
24
26
27
Job Trends
Bonus: Q2 2026 Job Market Update
In this bonus episode,
BioSpace
Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.
July 14, 2026
·
1 min read
·
Angela Gabriel
Alzheimer’s disease
AAIC 2026: Biogen delivers hope, validation with anti-tau Alzheimer’s win
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
July 14, 2026
·
5 min read
·
Heather McKenzie
Press Releases
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
July 14, 2026
·
4 min read
Press Releases
ALZHEIMER’S BLOOD TEST COULD BRING HIGHLY ACCURATE DIAGNOSIS INTO EVERYDAY CLINICAL CARE
July 14, 2026
·
6 min read
Press Releases
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
July 14, 2026
·
4 min read
Press Releases
Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
July 14, 2026
·
4 min read
Press Releases
Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders
July 14, 2026
·
3 min read
Press Releases
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
July 14, 2026
·
8 min read
Press Releases
Biovica Receives Ninth Work Order From a Leading Global Pharmaceutical Customer
July 14, 2026
·
2 min read
Press Releases
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
July 14, 2026
·
5 min read
1 of 11
Next
